Mundipharma
Neil started his legal career in 2002 when he joined London-based firm Bristows, specializing in intellectual property law. He moved in 2007 to Chicago, USA, obtaining his Juris Doctor from Northwestern University while working at the IP specialist firm, Banner & Witcoff, where he subsequently became a partner. In 2012, Neil returned to the UK to join Powell Gilbert LLP, continuing to specialize in patent litigation and advisory work in both high-tech and life sciences fields.
Neil joined the Mundipharma network in May 2015 as Director of European IP Strategy, moving quickly to Chief International IP Counsel.
Prior to studying law, Neil was awarded a PhD in biotechnology in 2001 from Cambridge University, UK, and he also holds a degree in molecular biology and biochemistry from Durham University, UK.
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.